Independent 5-year pharmaceutical and healthcare industry forecasts for Bahrain.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Bahraini pharmaceutical and healthcare industry.
Competitive intelligence, Bahraini pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Bahraini market.
The Bahrain Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Its Bahrain Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Bahraini pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark Its Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Bahrain to test other views – a key input for successful budgeting and strategic business planning in the Bahraini pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Bahraini Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bahrain.
Exploit The Latest Competitive Bahraini Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Bahrain.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Its forecast analysis, and taken together with Its Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
It 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
It 5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of Bahrain
Bahrain’s drug market is relatively small by regional standards, worth only US$49.2mn in 2005, although growth is expected to be strong in the coming years, with the market size expected to almost double by 2010. Branded medicines will continue to account for the bulk of the pharmaceutical market, although they will slowly lose share to generics, from the present 96%. Over-the-counter (OTC) medicines generate a fraction of the total market value, at 5% in 2005, with the percentage forecast to remain static throughout the forecast period.
Overall, however, solid economic growth and a rapidly expanding population are two macro factors that are helping to pull the market upwards. The healthcare system is undergoing rapid modernisation, with the government focusing on improving primary care. It has announced a scheme that will see all expatriate workers covered by private health insurance by 2013. This will reduce public health expenditure and is part of a government strategy to offload more of the burden of health spending to the private sector. The emergence of more civilisation-
Its adjusted Business Environment Rankings for the Middle East reveal that Bahrain is in 2nd place behind only the UAE. This is primarily due to forecasts of high market growth, coupled with the country’s world class intellectual property (IP) regime. Bahrain’s limited domestic manufacturing industry and lack of technological capabilities have also made the country an excellent investment opportunity for foreign drugmakers, although the outlook is tempered somewhat by the small overall market size.
Bahrain’s recent free trade agreement (FTA) with the US should also have a beneficial impact on multinational presence in the country, which exclusively comprises imports. As well as making USproduced drugs more available, the FTA has significantly tightened Bahrain’s intellectual property laws, which will in turn encourage foreign investment in the market. The domestic manufacturing sector is small, comprising just four companies producing basic drugs. However, Bahrain Industrial Pharmaceutical (Bidapharm), currently a pharmaceuticals importer, is in the process of building a manufacturing plant, which will make it the country’s fifth producer.
For more information, Please visit :
http://www.bharatbook.com/
